Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

12 Background: Approximately 20% of mCRPC has alterations in genes associated with HRR and is responsive to PARP inhibitors (PARPi) such as NIRA. Combined PARPi with androgen receptor pathway targeting may also benefit unselected mCRPC. MAGNITUDE assessed whether adding NIRA to AAP improves outcomes in pts with mCRPC with or without alterations in HRR associated genes. Methods: MAGNITUDE...

  • 123456 Profile photo of Madelyn

    MAGNITUDE study of niraparib + abiraterone/prednisone. reasonable option for men with HRR deficient prostate cancer who were otherwise eligible for PARP inhibitors.